LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

Strona główna・Stock List・CytoSorbents Corp

CytoSorbents Corp

Closed

SectorHealthcare

0.47

Buy Sell

Overview

Share price change

24h

Current

Min

0.44

Max

0.48

Key metrics
By Trading Economics
Income	368K -5.1M
Sales	-370K 8.9M
EPS	-0.08
Profit margin	-57.863
Employees	129
EBITDA	648K -3M

Recommendations
By TipRanks
Recommendations	Neutral
12 Months Forecast	+53.06% upside

Dividends
By Dow Jones
Next Earnings	6 sie 2026

Market Stats
By TradingEconomics
Market Cap	-10M 29M
Previous open	0.47
Previous close	0.47

News Sentiment

By Acuity

100%

319 / 344 Ranking in Healthcare

CytoSorbents Corp Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

3 cze 2026, 23:22 UTC

Earnings

Major Market Movers

Broadcom Shares Slide Despite Jump in 2Q Revenue on AI Chip Demand -- Update

3 cze 2026, 23:09 UTC

Hot Stocks

Stocks to Watch: Broadcom, CrowdStrike, PVH, Petco

3 cze 2026, 20:51 UTC

Earnings

Costco Reports 15% Sales Growth in May

3 cze 2026, 20:43 UTC

Earnings

Broadcom 2Q Revenue Climbs on AI Chip Demand

3 cze 2026, 23:48 UTC

Market Talk

Nikkei May Fall Amid Renewed Concerns About Iran Conflict -- Market Talk

3 cze 2026, 23:48 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

3 cze 2026, 23:35 UTC

Market Talk

Oil Futures Fall on Possible Technical Correction -- Market Talk

3 cze 2026, 23:15 UTC

Market Talk

Earnings

Five Below, Broadcom and Crowdstrike Fall Despite Solid Results -- Market Talk

3 cze 2026, 22:08 UTC

Hot Stocks

After-Hours Stocks to Watch: CrowdStrike, Broadcom, Five Below -- WSJ

3 cze 2026, 21:54 UTC

Market Talk

Correction to Oil Futures Rise on Concerns About U.S.-Iran Talks Article on June 1

3 cze 2026, 21:18 UTC

Earnings

Broadcom's Non-AI Semiconductor Revenue Rose 6% in 2Q, CEO Says

3 cze 2026, 21:15 UTC

Earnings

Broadcom CEO: Google Partnership Continues to Be 'Very Substantial'

3 cze 2026, 21:13 UTC

Earnings

Broadcom CEO Expects AI Semiconductor Revenue Growth to Continue in Fiscal 2028

3 cze 2026, 21:13 UTC

Earnings

Broadcom Continues to Expect AI Semiconductor Revenue of More Than $100B in 2027, CEO Says

3 cze 2026, 21:12 UTC

Earnings

Broadcom Expects AI Semiconductor Revenue of $56B This Year, CEO Says

3 cze 2026, 21:09 UTC

Earnings

Broadcom CEO: Networking Made Up Almost 40% of AI Revenue in 2Q

3 cze 2026, 21:03 UTC

Earnings

Broadcom Stock Falls After Earnings. Here's Why. -- Barrons.com

3 cze 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

3 cze 2026, 20:43 UTC

Earnings

CrowdStrike Stock Falls Despite Earnings Beat -- Barrons.com

3 cze 2026, 20:39 UTC

Acquisitions, Mergers, Takeovers

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 4th Update

3 cze 2026, 20:37 UTC

Acquisitions, Mergers, Takeovers

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 3rd Update

3 cze 2026, 20:35 UTC

Earnings

Broadcom Stock Falls Despite Record Results -- Barrons.com

3 cze 2026, 20:21 UTC

Acquisitions, Mergers, Takeovers

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 2nd Update

3 cze 2026, 20:17 UTC

Earnings

Broadcom 2Q Semiconductor Solutions Revenue $15B >AVGO

3 cze 2026, 20:17 UTC

Earnings

Broadcom Sees 3Q Semiconductor Revenue From AI $16B >AVGO

3 cze 2026, 20:15 UTC

Acquisitions, Mergers, Takeovers

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- Update

3 cze 2026, 20:15 UTC

Earnings

Broadcom 2Q Adj EPS $2.44 >AVGO

3 cze 2026, 20:15 UTC

Earnings

Broadcom 2Q EPS $1.91 >AVGO

3 cze 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

3 cze 2026, 20:15 UTC

Earnings

Broadcom 2Q Rev $22.19B >AVGO

Peer Comparison

Price change

CytoSorbents Corp Forecast

Price Target

By TipRanks

53.06% upside

12 Months Forecast

Average 0.75 USD 53.06%

High 0.75 USD

Low 0.75 USD

Based on 1 Wall Street analysts offering 12 month price targets forCytoSorbents Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

1 ratings

Buy

Hold

Sell

Based on 1 analysts giving stock ratings to CytoSorbents Corp - Dist in the past 3 months.

Sentiment

By Acuity

319 / 344 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About CytoSorbents Corp

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.